The thyroid-brain interaction in thyroid disorders and mood disorders

Journal of Neuroendocrinology

Volumn 20, Issue 10, 2008, Pages 1101-1114

  Bauer, Michael ^a   Goetz, T ^a   Glenn, T ^c   Whybrow, P C ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ChronoRecord Association Inc   (United States)

Author keywords

Brain; Hypothyroidism; Mood disorders; Neuropsychiatry; Thyroid hormone

Indexed keywords

LIOTHYRONINE; PAROXETINE; SERTRALINE; THYROID HORMONE; THYROXINE; TRICYCLIC ANTIDEPRESSANT AGENT;

BRAIN METABOLISM; CLINICAL TRIAL; DRUG MEGADOSE; HORMONE METABOLISM; HUMAN; MENTAL DISEASE; METHODOLOGY; MONOTHERAPY; MOOD DISORDER; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; THYROID DISEASE; THYROID FUNCTION; UNSPECIFIED SIDE EFFECT;

BRAIN; COGNITION DISORDERS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MOOD DISORDERS; THYROID DISEASES; THYROID GLAND; THYROID HORMONES; TISSUE EXTRACTS;

EID: 51449093922     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2008.01774.x     Document Type: Review

References (222)

1. Porterfield SP, Hendrich CE. The role of thyroid hormones in prenatal and neonatal neurological development -current perspectives. Endocr Rev 1993; 14: 94-106.
2. Bernal J, Nunez J. Thyroid hormones and brain development. Eur J Endocrinol 1995; 133: 390-398.
3. Bauer MS, Whybrow PC. Thyroid hormones and the central nervous system in affective illness: Interactions that may have clinical significance. Integr Psychiatry 1988; 6: 75-100.
4. Denicoff KD, Joffe RT, Lakshmanan MC, Robbins J, Rubinow DR. Neuropsychiatric manifestations of altered thyroid state. Am J Psychiatry 1990; 147: 94-99.
5. Haggerty JJ Jr, Prange AJ Jr. Borderline hypothyroidism and depression. Annu Rev Med 1995; 46: 37-46.
6. Sokoloff L, Wechsler RL, Mangold R, Balls K, Kety SS. Cerebral blood flow and oxygen consumption in hyperthyroidism before and after treatment. J Clin Invest 1953; 32: 202-208.
7. Sensenbach W, Madison L, Eisenberg S, Ochs L. The cerebral circulation and metabolism in hyperthyroidism and myxedema. J Clin Invest 1954; 33: 1434-1440.
8. Oppenheimer JH. Evolving concepts of thyroid hormone action. Biochimie 1999; 81: 539-543.
9. Shupnik MA, Ridgway EC, Chin WW. Molecular biology of thyrotropin. Endocr Rev 1989; 10: 459-475.
10. Kopp P. Thyroid hormone synthesis. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid. A Fundamental and Clinical Text, 9th edn. Philadelphia: Lippincott Williams & Wilkins, 2005: 52-76.
11. Larsen PR, Silva JE, Kaplan MM. Relationships between circulating and intracellular thyroid hormones: Physiological and clinical implications. Endocr Rev 1981; 2: 87-102.
12. van Doorn J, Roelfsema F, van der Heide D. Concentrations of thyroxine and 3,5,3′-triiodothyronine at 34 different sites in euthyroid rats as determined by an isotopic equilibrium technique. Endocrinology 1985; 117: 1201-1208.
13. Robbins J, Lakshmanan M. The movement of thyroid hormones in the central nervous system. Acta Med Austriaca 1992; 19 (Suppl. 1): 21-25.
14. Hennemann G, Docter R, Friesema EC, de Jong M, Krenning EP, Visser TJ. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev 2001; 22: 451-476.
15. Palha JA, Fernandes R, de Escobar GM, Episkopou V, Gottesman M, Saraiva MJ. Transthyretin regulates thyroid hormone levels in the choroid plexus, but not in the brain parenchyma: Study in a transthyretin-null mouse model. Endocrinology 2000; 141: 3267-3272.
16. Campos-Barros A, Hoell T, Musa A, Sampaolo S, Stoltenburg G, Pinna G, Eravci M, Meinhold H, Baumgartner A. Phenolic and tyrosyl ring iodothyronine deiodination and thyroid hormone concentrations in the human central nervous system. J Clin Endocrinol Metab 1996; 81: 2179-2185.
17. Leonard JL. Regulation of T3 production in the brain. Acta Med Austriaca 1992; 19 (Suppl. 1): 5-8.
18. Dratman MB, Crutchfield FL, Gordon JT, Jennings AS. Iodothyronine homeostasis in rat brain during hypo- and hyperthyroidism. Am J Physiol 1983; 245: E185-E193.
19. Kundu S, Pramanik M, Roy S, De J, Biswas A, Ray AK. Maintenance of brain thyroid hormone level during peripheral hypothyroid condition in adult rat. Life Sci 2006; 79: 1450-1455.
20. Bernal J. Action of thyroid hormone in brain. J Endocrinol Invest 2002; 25: 268-288.
21. St Germain DL, Galton VA. The deiodinase family of selenoproteins. Thyroid 1997; 7: 655-668.
22. Kohrle J. Local activation and inactivation of thyroid hormones: The deiodinase family. Mol Cell Endocrinol 1999; 151: 103-119.
23. Guadaño-Ferraz A, Obregón MJ, St Germain DL, Bernal J. The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain. Proc Natl Acad Sci USA 1997; 94: 10391-10396.
24. Galton VA, Wood ET, St Germain EA, Withrow CA, Aldrich G, St Germain GM, Clark AS, St Germain DL. Thyroid hormone homeostasis and action in the type 2 deiodinase-deficient rodent brain during development. Endocrinology 2007; 148: 3080-3088.
25. Schneider MJ, Fiering SN, Pallud SE, Parlow AF, St Germain DL, Galton VA. Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T4. Mol Endocrinol 2001; 15: 2137-2148.
26. Tu HM, Legradi G, Bartha T, Salvatore D, Lechan RM, Larsen PR. Regional expression of the type 3 iodothyronine deiodinase messenger ribonucleic acid in the rat central nervous system and its regulation by thyroid hormone. Endocrinology 1999; 140: 784-790.
27. Escámez MJ, Guadaño-Ferraz A, Cuadrado A, Bernal J. Type 3 iodothyronine deiodinase is selectively expressed in areas related to sexual differentiation in the newborn rat brain. Endocrinology 1999; 140: 5443-5446.
28. Santini F, Pinchera A, Ceccarini G, Castagna M, Rosellini V, Mammoli C, Montanelli L, Zucchi V, Chopra IJ, Chiovato L. Evidence for a role of the type IIIiodothyronine deiodinase in the regulation of 3,5,3′-triiodothyronine content in the human central nervous system. Eur J Endocrinol 2001; 144: 577-583.
29. Kester MH, Martinez de Mena R, Obregon MJ, Marinkovic D, Howatson A, Visser TJ, Hume R, Morreale de Escobar G. Iodothyronine levels in the human developing brain: Major regulatory roles of iodothyronine deiodinases in different areas. J Clin Endocrinol Metab 2004; 89: 3117-3128.
30. Friesema EC, Jansen J, Visser TJ. Thyroid hormone transporters. Biochem Soc Trans 2005; 33: 228-232.
31. Visser WE, Friesema ECH, Jansen J, Visser TJ. Thyroid hormone transport in and out of cells. Trends Endocrinol Metabol 2008; 19: 50-56.
32. Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003; 278: 40128-40135.
33. Heuer H, Maier MK, Iden S, Mittag J, Friesema EC, Visser TJ, Bauer K. The monocarboxylate transporter 8 linked to human psychomotor retardation is highly expressed in thyroid hormone-sensitive neuron populations. Endocrinology 2005; 146: 1701-1706.
34. Alkemade A, Friesema EC, Unmehopa UA, Fabriek BO, Kuiper GG, Leonard JL, Wiersinga WM, Swaab DF, Visser TJ, Fliers E. Neuroanatomical pathways for thyroid hormone feedback in the human hypothalamus. J Clin Endocrinol Metab 2005; 90: 4322-4334.
35. Alkemade A, Friesema EC, Kuiper GG, Wiersinga WM, Swaab DF, Visser TJ, Fliers E. Novel neuroanatomical pathways for thyroid hormone action in the human anterior pituitary. Eur J Endocrinol 2006; 154: 491-500.
36. Friesema EC, Grueters A, Biebermann H, Krude H, von Moers A, Reeser M, Barrett TG, Mancilla EE, Svensson J, Kester MH, Kuiper GG, Balkassmi S, Uitterlinden AG, Koehrle J, Rodien P, Halestrap AP, Visser TJ. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 2004; 364: 1435-1437.
37. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 2002; 16: 2283-2296.
38. Sugiyama D, Kusuhara H, Taniguchi H, Ishikawa S, Nozaki Y, Aburatani H, Sugiyama Y. Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: High affinity transporter for thyroxine. J Biol Chem 2003; 278: 43489-43495.
39. Tohyama K, Kusuhara H, Sugiyama Y. Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology 2004; 145: 4384-4391.
40. Chu C, Li JY, Boado RJ, Pardridge WM. Blood-brain barrier genomics and cloning of a novel organic anion transporter. J Cereb Blood Flow Metab 2008; 28: 291-301.
41. Fliers E, Unmehopa UA, Alkemade A. Functional neuroanatomy of thyroid hormone feedback in the human hypothalamus and pituitary gland. Mol Cell Endocrinol 2006; 251: 1-8.
42. Alkemade A, Unmehopa UA, Brouwer JP, Hoogendijk WJ, Wiersinga WM, Swaab DF, Fliers E. Decreased thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus of patients with major depression. Mol Psychiatry 2003; 8: 838-839.
43. Alkemade A, Unmehopa UA, Wiersinga WM, Swaab DF, Fliers E. Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus. J Clin Endocrinol Metab 2005; 90: 323-327.
44. Baqui M, Botero D, Gereben B, Curcio C, Harney JW, Salvatore D, Sorimachi K, Larsen PR, Bianco AC. Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes. J Biol Chem 2003; 278: 1206-1211.
45. Lechan RM, Toni R. Thyroid hormones in neural tissue. In: Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT, eds. Hormones, Brain and Behavior. San Diego: Academic Press, 2002: 157-238.
46. Schwartz HL, Oppenheimer JH. Nuclear triiodothyronine receptor sites in brain: Probable identity with hepatic receptors and regional distribution. Endocrinology 1978; 103: 267-273.
47. Dratman MB, Futaesaku Y, Crutchfield FL, Berman N, Payne B, Sar M, Stumpf WE. Iodine-125-labeled triiodothyronine in rat brain: Evidence for localization in discrete neural systems. Science 1982; 215: 309-312.
48. Ruel J, Faure R, Dussault JH. Regional distribution of nuclear T3 receptors in rat brain and evidence for preferential localization in neurons. J Endocrinol Invest 1985; 8: 343-348.
49. Koenig RJ. Thyroid hormone receptor coactivators and corepressors. Thyroid 1998; 8: 703-713.
50. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001; 81: 1097-1142.
51. Hsu JH, Brent GA. Thyroid hormone receptor gene knockouts. Trends Endocrinol Metab 1998; 9: 103-112.
52. Guadaño-Ferraz A, Benavides-Piccione R, Venero C, Lancha C, Vennström B, Sandi C, DeFelipe J, Bernal J. Lack of thyroid hormone receptor alpha1 is associated with selective alterations in behavior and hippocampal circuits. Mol Psychiatry 2003; 8: 30-38.
53. Venero C, Guadaño-Ferraz A, Herrero AI, Nordström K, Manzano J, de Escobar GM, Bernal J, Vennström B. Anxiety, memory impairment, and locomotor dysfunction caused by a mutant thyroid hormone receptor alpha1 can be ameliorated by T3 treatment. Genes Dev 2005; 19: 2152-2163.
54. Hauser P, Zametkin AJ, Martinez P, Vitiello B, Matochik JA, Mixson AJ, Weintraub BD. Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone. N Engl J Med 1993; 328: 997-1001.
55. McDonald MP, Wong R, Goldstein G, Weintraub B, Cheng SY, Crawley JN. Hyperactivity and learning deficits in transgenic mice bearing a human mutant thyroid hormone beta1 receptor gene. Learn Mem 1998;5: 289-301.
56. Siesser WB, Zhao J, Miller LR, Cheng SY, McDonald MP. Transgenic mice expressing a human mutant beta1 thyroid receptor are hyperactive, impulsive, and inattentive. Genes Brain Behav 2006; 5: 282-297.
57. Storey NM, Gentile S, Ullah H, Russo A, Muessel M, Erxleben C, Armstrong DL. Rapid signaling at the plasma membrane by a nuclear receptor for thyroid hormone. Proc Natl Acad Sci USA 2006; 103: 5197-51201.
58. Hiroi Y, Kim HH, Ying H, Furuya F, Huang Z, Simoncini T, Noma K, Ueki K, Nguyen NH, Scanlan TS, Moskowitz MA, Cheng SY, Liao JK. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 2006; 103: 14104-14109.
59. Whybrow PC, Prange AJ Jr. A hypothesis of thyroid-catecholamine-receptor interaction. Arch Gen Psychiatr 1981; 38: 106-113.
60. Marwaha J, Prasad KN. Hypothyroidism elicits electrophysiological noradrenergic subsensitivity in rat cerebellum. Science 1981; 214: 675-677.
61. Gordon JT, Kaminski DM, Rozanov CB, Dratman MB. Evidence that 3,3′,5-triiodothyronine is concentrated in and delivered from the locus coeruleus to its noradrenergic targets via anterograde axonal transport. Neuroscience 1999; 93: 943-954.
62. Bauer M, Heinz A, Whybrow PC. Thyroid hormones, serotonin and mood: Of synergy and significance in the adult brain. Mol Psychiatr 2002; 7: 140-156.
63. Mason GA, Bondy SC, Nemeroff CB, Walker CH, Prange AJ Jr. The effects of thyroid state on beta-adrenergic and serotonergic receptors in rat brain. Psychoneuroendocrinology 1987; 12: 261-270.
64. Henley WN, Koehnle TJ. Thyroid hormones and the treatment of depression: An examination of basic hormonal actions in the mature mammalian brain. Synapse 1997; 27: 36-44.
65. Bauer M, Whybrow PC. Thyroid hormone, brain, and behavior. In: Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT, eds. Hormones, Brain and Behavior. San Diego: Academic Press, 2002: 238-264.
66. Mano T, Sakamoto H, Fujita K, Makino M, Kakizawa H, Nagata M, Kotake M, Hamada M, Uchimura K, Hayakawa N, Hayashi R, Nakai A, Itoh M, Kuzuya H, Nagasaka A. Effects of thyroid hormone on catecholamine and its metabolite concentrations in rat cardiac muscle and cerebral cortex. Thyroid 1998; 8: 353-358.
67. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorders. II. Treatment of refractory rapid cycling with high-dose levothyroxine: A preliminary study. Arch Gen Psychiatr 1990; 47: 435-440.
68. Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: An open clinical trial. Neuropsychopharmacol 1994; 10: 183-189.
69. Jackson IM. The thyroid axis and depression. Thyroid 1998; 8: 951-956.
70. Gyulai L, Bauer M, Bauer MS, Garcia-Espana F, Cnaan A, Whybrow PC. Thyroid hypofunction in patients with rapid-cycling bipolar disorder after lithium challenge. Biol Psychiatry 2003; 53: 899-905.
71. Sinclair D. Clinical and laboratory aspects of thyroid autoantibodies. Ann Clin Biochem 2006; 43: 173-183.
72. Whybrow PC, Prange AJ Jr, Treadway CR. Mental changes accompanying thyroid gland dysfunction. Arch Gen Psychiatry 1969; 20: 48-63.
73. Whybrow PC, Bauer M. Behavioral and psychiatric aspects of hypothyroidism. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid. A Fundamental and Clinical Text, 9th edn. Philadelphia: Lippincott Williams & Wilkins, 2005: 842-849.
74. Whybrow PC, Bauer M. Behavioral and psychiatric aspects of thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid. A Fundamental and Clinical Text, 9th edn. Philadelphia: Lippincott Williams & Wilkins, 2005: 644-650.
75. Haupt M, Kurz A. Reversibility of dementia in hypothyroidism. J Neurol 1993; 240: 333-335.
76. Davis JD, Stern RA, Flashman LA. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. Minerva Endocrinol 2007; 32: 49-65.
77. Stern RA, Robinson B, Thorner AR, Arruda JE, Prohaska ML, Prange AJ Jr. A survey study of neuropsychiatric complaints in patients with Graves'disease. J Neuropsychiatry Clin Neurosci 1996; 8: 181-185.
78. Vogel A, Elberling TV, Hørding M, Dock J, Rasmussen AK, Feldt-Rasmussen U, Perrild H, Waldemar G. Affective symptoms and cognitive functions in the acute phase of Graves'thyrotoxicosis. Psychoneuroendocrinology 2007; 32: 36-43.
79. Zeitlhofer J, Saletu B, Stary J, Ahmadi R. Cerebral function in hyperthyroid patients. Psychopathology, psychometric variables, central arousal and time perception before and after thyreostatic therapy. Neuropsychobiology 1984; 11: 89-93.
80. Haggerty JJ Jr, Evans DL, Prange AJ Jr. Organic brain syndrome associated with marginal hypothyroidism. Am J Psychiatry 1986; 143: 785-786.
81. Osterweil D, Syndulko K, Cohen SN, Pettler-Jennings PD, Hershman JM, Cummings JL, Tourtellotte WW, Solomon DH. Cognitive function in nondemented older adults with hypothyroidism. J Am Geriatr Soc 1992; 40: 325-335.
82. Dugbartey AT. Neurocognitive aspects of hypothyroidism. Arch Intern Med 1998; 158: 1413-1418.
83. Burmeister LA, Ganguli M, Dodge HH, Toczek T, DeKosky ST, Nebes RD. Hypothyroidism and cognition: Preliminary evidence for a specific defect in memory. Thyroid 2001; 11: 1177-1185.
84. Jaeschke R, Guyatt G, Gerstein H, Patterson C, Molloy W, Cook D, Harper S, Griffith L, Carbotte R. Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 1996; 11: 744-749.
85. Miller KJ, Parsons TD, Whybrow PC, van Herle K, Rasgon N, van Herle A, Martinez D, Silverman DH, Bauer M. Memory improvement with treatment of hypothyroidism. Int J Neurosci 2006; 116: 895-906.
86. Miller KJ, Parsons TD, Whybrow PC, Van Herle K, Rasgon N, Van Herle A, Martinez D, Silverman DH, Bauer M. Verbal memory retrieval deficits associated with untreated hypothyroidism. J Neuropsychiatry Clin Neurosci 2007; 19: 132-136.
87. Davis JD, Stern RA, Flashman LA. Cognitive and neuropsychiatric aspects of subclinical hypothyroidism: Significance in the elderly. Curr Psychiatry Rep 2003; 5: 384-390.
88. Ross DS. Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease. Endocrinol Metab Clin North Am 2001; 30: 245-264.
89. Luboshitzky R, Oberman AS, Kaufman N, Reichman N, Flatau E. Prevalence of cognitive dysfunction and hypothyroidism in an elderly community population. Isr J Med Sci 1996; 32: 60-65.
90. Bono G, Fancellu R, Blandini F, Santoro G, Mauri M. Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment. Acta Neurol Scand 2004; 110: 59-66.
91. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frölich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004; 292: 2591-2599.
92. Jorde R, Waterloo K, Storhaug H, Nyrnes A, Sundsfjord J, Jenssen TG. Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. J Clin Endocrinol Metab 2006; 91: 145-153.
93. Monzani F, Del Guerra P, Caraccio N, Pruneti CA, Pucci E, Luisi M, Baschieri L. Subclinical hypothyroidism: Neurobehavioral features and beneficial effect of Lthyroxine treatment. Clin Investig 1993; 71: 367-371.
94. Baldini IM, Vita A, Mauri MC, Amodei V, Carrisi M, Bravin S, Cantalamessa L. Psychopathological and cognitive features in subclinical hypothyroidism. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21: 925-935.
95. del Ser Quijano T, Delgado C, Martínez Espinosa S, Vázquez C. Cognitive deficiency in mild hypothyroidism. Neurologia 2000; 15: 193-198.
96. Zhu DF, Wang ZX, Zhang DR, Pan ZL, He S, Hu XP, Chen XC, Zhou JN. fMRI revealed neural substrate for reversible working memory dysfunction in subclinical hypothyroidism. Brain 2006; 129: 2923-2930.
97. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-238.
98. Patten SB, Williams JV, Esposito E, Beck CA. Self-reported thyroid disease and mental disorder prevalence in the general population. Gen Hosp Psychiatry 2006; 28: 503-508.
99. Engum A, Bjøro T, Mykletun A, Dahl AA. An association between depression, anxiety and thyroid function-a clinical fact or an artefact? Acta Psychiatr Scand 2002; 106: 27-34.
100. Thomsen AF, Kvist TK, Andersen PK, Kessing LV. Increased risk of developing affective disorder in patients with hypothyroidism: A register-based study. Thyroid 2005; 15: 700-707.
101. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate'doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf) 2002; 57: 577-585.
102. Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JG, Wiersinga WM. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 2005; 153: 747-753.
103. Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS. Health status, psychological symptoms, mood, and cognition in L-thyroxine-treated hypothyroid subjects. Thyroid. 2007; 17: 249-258.
104. Walsh JP, Ward LC, Burke V, Bhagat CI, Shiels L, Henley D, Gillett MJ, Gilbert R, Tanner M, Stuckey BG. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: Results of a double-blind, randomized clinical trial. J Clin Endocrinol Metab 2006; 91: 2624-2630.
105. Saravanan P, Visser TJ, Dayan CM. Psychological well-being correlates with free thyroxine but not free 3,5,3′-triiodothyronine levels in patients on thyroid hormone replacement. J Clin Endocrinol Metab 2006; 91: 3389-3393.
106. Pop VJ, Maartens LH, Leusink G, van Son MJ, Knottnerus AA, Ward AM, Metcalfe R, Weetman AP. Are autoimmune thyroid dysfunction and depression related? J Clin Endocrinol Metab 1998; 83: 3194-3197.
107. Siegmund W, Spieker K, Weike AI, Giessmann T, Modess C, Dabers T, Kirsch G, Sänger E, Engel G, Hamm AO, Nauck M, Meng W. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14: 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) 2004; 60: 750-757.
108. Kuijpens JL, Vader HL, Drexhage HA, Wiersinga WM, van Son MJ, Pop VJ. Thyroid peroxidase antibodies during gestation are a marker for subsequent depression postpartum. Eur J Endocrinol 2001; 145: 579-584.
109. Harris B, Oretti R, Lazarus J, Parkes A, John R, Richards C, Newcombe R, Hall R. Randomised trial of thyroxine to prevent postnatal depression in thyroidantibody-positive women. Br J Psychiatry 2002; 180: 327-330.
110. Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: Syndrome or myth? Arch Neurol 2003; 60: 164-171.
111. Ganguli M, Burmeister LA, Seaberg EC, Belle S, DeKosky ST. Association between dementia and elevated TSH: A community-based study. Biol Psychiatry 1996; 40: 714-725.
112. Latasa MJ, Belandia B, Pascual A. Thyroid hormones regulate beta-amyloid gene splicing and protein secretion in neuroblastoma cells. Endocrinology 1998; 139: 2692-2698.
113. de Jong FJ, den Heijer T, Visser TJ, de Rijke YB, Drexhage HA, Hofman A, Breteler MM. Thyroid hormones, dementia, and atrophy of the medial temporal lobe. J Clin Endocrinol Metab 2006; 91: 2569-2573.
114. Roberts LM, Pattison H, Roalfe A, Franklyn J, Wilson S, Hobbs FD, Parle JV. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med 2006; 145: 573-581.
115. van Osch LA, Hogervorst E, Combrinck M, Smith AD. Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology 2004; 62: 1967-1971.
116. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf) 2000; 53: 733-737.
117. Sampaolo S, Campos-Barros A, Mazziotti G, Carlomagno S, Sannino V, Amato G, Carella C, Di Iorio G. Increased cerebrospinal fluid levels of 3,3′,5′-triiodothyronine in patients with Alzheimer's disease. J Clin Endocrinol Metab 2005; 90: 198-202.
118. Yoshimasu F, Kokmen E, Hay ID, Beard CM, Offord KP, Kurland LT. The association between Alzheimer's disease and thyroid disease in Rochester, Minnesota. Neurology 1991; 41: 1745-1747.
119. Lopez O, Huff FJ, Martinez AJ, Bedetti CD. Prevalence of thyroid abnormalities is not increased in Alzheimer's disease. Neurobiol Aging 1989; 10: 247-251.
120. Taylor JW. Depression in thyrotoxicosis. Am J Psychiatry 1975; 132: 552-553.
121. Kathol RG, Delahunt JW. The relationship of anxiety and depression to symptoms of hyperthyroidism using operational criteria. Gen Hosp Psychiatry 1986; 8: 23-28.
122. Trerzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J. A psychiatric and neuropsychological study of patients with untreated Graves'disease. Gen Hosp Psychiatry 1988; 10: 49-55.
123. Bursten B. Psychoses associated with thyrotoxicosis. Arch Gen Psychiatry 1961; 4: 267-273.
124. Checkley SA. Thyrotoxicosis and the course of manic-depressive illness. Br J Psychiatry 1978; 133: 219-223.
125. Hasan MK, Mooney RP. Mania and thyrotoxicosis. J Fam Pract 1981; 13: 113.
126. Reus VI, Gold P, Post R. Lithium-induced thyrotoxicosis. Am J Psychiatry 1979; 136: 724-725.
127. Braverman LE, Utiger RD. Introduction to hypothyroidism. In: Werner & Ingbar's The Thyroid. A Fundamental and Clinical Text, 8th edn. Philadelphia: Lippincott Williams & Wilkins, 2000: 719-720.
128. Kinuya S, Michigishi T, Tonami N, Aburano T, Tsuji S, Hashimoto T. Reversible cerebral hypoperfusion observed with Tc-99m HMPAO SPECT in reversible dementia caused by hypothyroidism. Clin Nucl Med 1999; 24: 666-668.
129. Forchetti CM, Katsamakis G, Garron DC. Autoimmune thyroiditis and a rapidly progressive dementia: Global hypoperfusion on SPECT scanning suggests a possible mechanism. Neurology 1997; 49: 623-626.
130. Constant EL, de Volder AG, Ivanoiu A, Bol A, Labar D, Seghers A, Cosnard G, Melin J, Daumerie C. Cerebral blood flow and glucose metabolism in hypothyroidism: A positron emission tomography study. J Clin Endocrinol Metab 2001; 86: 3864-3870.
131. Krausz Y, Freedman N, Lester H, Newman JP, Barkai G, Bocher M, Chisin R, Bonne O. Regional cerebral blood flow in patients with mild hypothyroidism. J Nucl Med 2004; 45: 1712-1715.
132. Nagamachi S, Jinnouchi S, Nishii R, Ishida Y, Fujita S, Futami S, Kodama T, Tamura S, Kawai K. Cerebral blood flow abnormalities induced by transient hypothyroidism after thyroidectomy -analysis by tc-99m-HMPAO and SPM96. Ann Nucl Med 2004; 18: 469-477.
133. Schraml FV, Beason-Held LL, Fletcher DW, Brown BP. Cerebral accumulation of Tc-99m ethyl cysteinate dimer (ECD) in severe, transient hypothyroidism. J Cereb Blood Flow Metab 2006; 26: 321-329.
134. Krausz Y, Freedman N, Lester H, Barkai G, Levin T, Bocher M, Chisin R, Lerer B, Bonne O. Brain SPECT study of common ground between hypothyroidism and depression. Int J Neuropsychopharmacol 2007; 10: 99-106.
135. Bauer M, Schlagenhauf F, London E, Miller K, Whybrow PC, Rasgon N, van Herle K, van Herle AJ, Phelps ME, Silverman DHS. Effects of hypothyroidism on brain metabolism and its associations with neuropsychiatric impairments. Endocrine Abstracts 2006; 11: S16.
136. Guedj E, Taïeb D, De Laforte C, Ceccaldi M, Mundler O. Similitude of brain perfusion pattern in hypothyroidism and early Alzheimer's disease: Physiopathologic considerations. J Nucl Med 2005; 46: 1247.
137. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42: 85-94.
138. Steinling M, Defebvre L, Duhamel A, Lecouffe P, Lavenu I, Pasquier F, Charpentier P. Is there a typical pattern of brain SPECT imaging in Alzheimer's disease? Dement Geriatr Cogn Disord 2001; 12: 371-378.
139. Herholz K. PET studies in dementia. Ann Nucl Med 2003; 17: 79-89.
140. Fukui T, Hasegawa Y, Takenaka H. Hyperthyroid dementia: clinicoradiological findings and response to treatment. J Neurol Sci 2001; 184: 81-88.
141. Seo SW, Lee BI, Lee JD, Park SA, Kim KS, Kim SH, Yun MJ. Thyrotoxic autoimmune encephalopathy: A repeat positron emission tomography study. J Neurol Neurosurg Psychiatry 2003; 74: 504-506.
142. Piga M, Serra A, Deiana L, Loi GL, Satta L, Di Liberto M, Mariotti S. Brain perfusion abnormalities in patients with euthyroid autoimmune thyroiditis. Eur J Nucl Med Mol Imaging 2004; 31: 1639-1644.
143. Zettinig G, Asenbaum S, Fueger BJ, Hofmann A, Diemling M, Mittlboeck M, Dudczak R. Increased prevalence of sublinical brain perfusion abnormalities in patients with autoimmune thyroiditis: Evidence of Hashimoto's encephalitis? Clin Endocrinol (Oxf) 2003; 59: 637-643.
144. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48: 813-829.
145. Mayberg HS. Brain mapping: Depression. In: Toga AW, Mazziotta JC, Frackowiak RD, eds. Brain Mapping: The Diseases. San Diego: Academic Press, 2000: 485-507.
146. Videbech P. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: A critical review. Acta Psychiatr Scand 2000; 101: 11-20.
147. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: Towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003; 65: 193-207.
148. Milak MS, Parsey RV, Keilp J, Oquendo MA, Malone KM, Mann JJ. Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch Gen Psychiatry 2005; 62: 397-408.
149. Bauer M, London ED, Rasgon N, Berman SM, Frye MA, Altshuler LL, Mandelkern MA, Bramen J, Voytek B, Woods R, Mazziotta JC, Whybrow PC. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol Psychiatry 2005; 10: 456-469.
150. Marangell LB, Ketter TA, George MS, Pazzaglia PJ, Callahan AM, Parekh P, Andreason PJ, Horwitz B, Herscovitch P, Post RM. Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders. Am J Psychiatr 1997; 154: 224-230.
151. Gold MS, Pottash AL, Extein I. Hypothyroidism and depression. Evidence from complete thyroid function evaluation. JAMA 1981; 245: 1919-1922.
152. Nemeroff CB, Simon JS, Haggerty JJ Jr, Evans DL. Antithyroid antibodies in depressed patients. Am J Psychiatry 1985; 142: 840-843.
153. Joffe RT, Marriott M. Thyroid hormone levels and recurrence of major depression. Am J Psychiatry 2000; 157: 1689-1691.
154. Loosen PT. The TRH-induced TSH response in psychiatric patients: A possible neuroendocrine marker. Psychoneuroendocrinology 1985; 10:237-260.
155. Arem R, Cusi K. Thyroid function testing in psychiatric illness: usefulness and limitations. Trends Endocrinol Metab 1997; 8: 282-287.
156. Staner L, Linkowski P, Mendlewicz J. Biological markers as classifiers for depression: A multivariate study. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 899-914.
157. Rush AJ, Giles DE, Schlesser MA, Orsulak PJ, Weissenburger JE, Fulton CL, Fairchild CJ, Roffwarg HP. Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol Psychiatry 1997; 41: 915-928.
158. Whybrow PC, Coppen A, Prange AJ Jr, Noguera R, Bailey JE. Thyroid function and the response to liothyronine in depression. Arch Gen Psychiatry 1972; 26: 242-245.
159. Baumgartner A, Graf KJ, Kurten I, Meinhold H. The hypothalamic-pituitary-thyroid axis in psychiatric patients and healthy subjects. Parts 1-4. Psychiatry Res 1988; 24: 271-332.
160. Baumgartner A. [Thyroid hormones and depressive disorders -critical overview and perspectives. Part 1: Clinical aspects. Nervenarzt 1993; 64: 1-10.
161. Baumgartner A, Campos-Barros A. [Thyroid hormones and depressive disorders - clinical overview and perspectives. Part 2: Thyroid hormones and the central nervous system -basic research. Nervenarzt 1993; 64: 11-20.
162. Baumgartner A, Volz HP, Campos-Barros A, Stieglitz RD, Mansmann U, Mackert A. Serum concentrations of thyroid hormones in patients with nonseasonal affective disorders during treatment with bright and dim light. Biol Psychiatry 1996; 40: 899-907.
163. Joffe R, Segal Z, Singer W. Change in thyroid hormone levels following response to cognitive therapy for major depression. Am J Psychiatry 1996; 153: 411-413.
164. Eravci M, Pinna G, Meinhold H, Baumgartner A. Effects of pharmacological and nonpharmacological treatments on thyroid hormone metabolism and concentrations in rat brain. Endocrinology 2000; 141: 1027-1040.
165. Pinna G, Broedel O, Eravci M, Stoltenburg-Didinger G, Plueckhan H, Fuxius S, Meinhold H, Baumgartner A. Thyroid hormones in the rat amygdala as common targets for antidepressant drugs, mood stabilizers, and sleep deprivation. Biol Psychiatry 2003; 54: 1049-1059.
166. Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci 2007; 10: 1110-1115.
167. Montero-Pedrazuela A, Venero C, Lavado-Autric R, Fernández-Lamo I, García-Verdugo JM, Bernal J, Guadaño-Ferraz A. Modulation of adult hippocampal neurogenesis by thyroid hormones: implications in depressive-like behavior. Mol Psychiatry 2006; 11: 361-371.
168. Desouza LA, Ladiwala U, Daniel SM, Agashe S, Vaidya RA, Vaidya VA. Thyroid hormone regulates hippocampal neurogenesis in the adult rat brain. Mol Cell Neurosci 2005; 29: 414-426.
169. Ambrogini P, Cuppini R, Ferri P, Mancini C, Ciaroni S, Voci A, Gerdoni E, Gallo G. Thyroid hormones affect neurogenesis in the dentate gyrus of adult rat. Neuroendocrinology 2005; 81: 244-253.
170. Sullivan GM, Hatterer JA, Herbert J, Chen X, Roose SP, Attia E, Mann JJ, Marangell LB, Goetz RR, Gorman JM. Low levels of transthyretin in the CSF of depressed patients. Am J Psychiatry 1999; 156: 710-715.
171. Palha JA, Episkopou V, Maeda S, Shimada K, Gottesman ME, Saraiva MJ. Thyroid hormone metabolism in a transthyretin-null mouse strain. J Biol Chem 1994; 269: 33135-33139.
172. Schreiber G. The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J Endocrinol 2002; 175: 61-73.
173. Palha JA. Transthyretin as a thyroid hormone carrier: Function revisited. Clin Chem Lab Med 2002; 40: 1292-1300.
174. Frye MA, Denicoff KD, Bryan AL, Smith-Jackson EE, Ali SO, Luckenbaugh D, Leverich GS, Post RM. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatr 1999; 156: 1909-1914.
175. Cole DP, Thase ME, Mallinger AG, Soares JC, Luther JF, Kupfer DJ, Frank E. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry 2002; 159: 116-121.
176. Abulseoud O, Sane N, Cozzolino A, Kiriakos L, Mehra V, Gitlin M, Masseling S, Whybrow P, Altshuler LL, Mintz J, Frye MA. Free T4 index and clinical outcome in patients with depression. J Affect Disord 2007; 100: 271-277.
177. Kupka RW, Nolen WA, Post RM, McElroy SL, Altshuler LL, Denicoff KD, Frye MA, Keck PE Jr, Leverich GS, Rush AJ, Suppes T, Pollio C, Drexhage HA. High rate of autoimmune thyroiditis in bipolar disorder: Lack of association with lithium exposure. Biol Psychiatry 2002; 51: 305-311.
178. Haggerty JJ Jr, Evans DL, Golden RN, Pedersen CA, Simon JS, Nemeroff CB. The presence of antithyroid antibodies in patients with affective and nonaffective psychiatric disorders. Biol Psychiatry 1990; 27: 51-60.
179. Oomen HA, Schipperijn AJ, Drexhage HA. The prevalence of affective disorder and in particular of a rapid cycling of bipolar disorder in patients with abnormal thyroid function tests. Clin Endocrinol (Oxf) 1996; 45: 215-223.
180. Haggerty JJ Jr, Silva SG, Marquardt M, Mason GA, Chang HY, Evans DL, Golden RN, Pedersen C. Prevalence of antithyroid antibodies in mood disorders. Depress Anxiety 1997; 5: 91-96.
181. Hornig M, Amsterdam JD, Kamoun M, Goodman DB. Autoantibody disturbances in affective disorders: A function of age and gender? J Affect Disord 1999; 55: 29-37.
182. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489-499.
183. Hoogendoorn EH, Hermus AR, de Vegt F, Ross HA, Verbeek AL, Kiemeney LA, Swinkels DW, Sweep FC, den Heijer M. Thyroid function and prevalence of antithyroperoxidase antibodies in a population with borderline sufficient iodine intake: Influences of age and sex. Clin Chem 2006; 52: 104-111.
184. Pedersen IB, Knudsen N, Jørgensen T, Perrild H, Ovesen L, Laurberg P. Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency. Clin Endocrinol (Oxf) 2003; 58: 36-42.
185. O'Leary PC, Feddema PH, Michelangeli VP, Leedman PJ, Chew GT, Knuiman M, Kaye J, Walsh JP. Investigations of thyroid hormones and antibodies based on a community health survey: The Busselton thyroid study. Clin Endocrinol (Oxf) 2006; 64: 97-104.
186. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR; Guidelines Committee, National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13: 3-126.
187. Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE. NHANES III TSH:TPOAb relationships demonstrate that TSH upper reference Limits May be skewed by occult thyroid dysfunction. J Clin Endocrinol Metab 2007; 92: 4236-4240.
188. Bjoro T, Holmen J, Krüger O, Midthjell K, Hunstad K, Schreiner T, Sandnes L, Brochmann H. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol 2000; 143: 639-647.
189. Carta MG, Loviselli A, Hardoy MC, Massa S, Cadeddu M, Sardu C, Carpiniello B, Dell'Osso L, Mariotti S. The link between thyroid autoimmunity (antithyroid peroxidase autoantibodies) with anxiety and mood disorders in the community: A field of interest for public health in the future. BMC Psychiatry 2004; 4: 5.
190. Brouwer JP, Appelhof BC, Hoogendijk WJ, Huyser J, Endert E, Zuketto C, Schene AH, Tijssen JG, Van Dyck R, Wiersinga WM, Fliers E. Thyroid and adrenal axis in major depression: A controlled study in outpatients. Eur J Endocrinol 2005; 152: 185-191.
191. Vonk R, van der Schot AC, Kahn RS, Nolen WA, Drexhage HA. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry 2007; 62: 135-140.
192. Hillegers MH, Reichart CG, Wals M, Verhulst FC, Ormel J, Nolen WA, Drexhage HA. Signs of a higher prevalence of autoimmune thyroiditis in female offspring of bipolar parents. Eur Neuropsychopharmacol 2007; 17: 394-399.
193. Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, Morreale de Escobar G. REVIEW: Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J Clin Endocrinol Metab 2005; 90: 4946-4954.
194. Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: Comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf). 1988; 28: 325-333.
195. Gjessing R. Disturbances of somatic function in catatonia with a periodic course and their compensation. J Ment Sci 1938; 84: 608-621.
196. Prange AJ Jr, Wilson IC, Rabon AM, Lipton MA. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatr 1969; 126: 457-469.
197. Altshuler L, Bauer M, Frye M, Gitlin M, Mintz J, Szuba MP, Leight KL, Whybrow PC. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatr 2001; 158: 1617-1622.
198. Aronson R, Offman HJ, Joffe RT, Naylor D. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996; 53: 842-848.
199. Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, Drori T, Newman ME, Sackeim HA, Glaser B, Lerer B. Combined treatment with sertraline and liothyronine in major depression: A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64: 679-688.
200. Appelhof BC, Brouwer JP, van Dyck R, Fliers E, Hoogendijk WJ, Huyser J, Schene AH, Tijssen JG, Wiersinga WM. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J Clin Endocrinol Metab 2004; 89: 6271-6276.
201. Bauer M, Priebe S, Berghöfer A, Bschor T, Kiesslinger K, Whybrow PC. Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders. J Affect Disord 2001; 64: 35-42.
202. Bauer M, Berghöfer A, Bschor T, Baumgartner A, Kiesslinger U, Hellweg R, Adli M, Baethge C, Müller-Oerlinghausen B. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacol 2002; 27: 620-628.
203. Stancer HC, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Arch Gen Psychiatr 1982; 39: 311-312.
204. Rudas S, Schmitz M, Pichler P, Baumgartner A. Treatment of refractory chronic depression and dysthymia with high-dose thyroxine. Biol Psychiatr 1999; 2: 229-233.
205. Bauer M, Hellweg R, Gräf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacol 1998; 18: 444-455.
206. Gyulai L, Whybrow PC, Jaggi J, Bauer MS, Younkin S, Rubin L, Attie M. Bone mineral density and L-thyroxine treatment in rapidly cycling bipolar disorder. Biol Psychiatr 1997; 41: 503-506.
207. Gyulai L, Bauer M, Espana-Garcia F, Hierholzer J, Baumgartner A, Whybrow PC. Bone mineral density in pre- and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord 2001; 66: 185-191.
208. Bauer M, Fairbanks L, Berghöfer A, Hierholzer J, Bschor T, Baethge C, Rasgon N, Sasse J, Whybrow PC. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: A longitudinal study. J Affect Disord 2004; 83: 183-190.
209. Bauer M, Baur H, Berghöfer A, Ströhle A, Hellweg R, Müller-Oerlinghausen B, Baumgartner A. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. J Affect Disord 2002; 68: 285-294.
210. Refetoff S. Resistance to thyroid hormone. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid. A Fundamental and Clinical Text, 8th edn. Philadelphia: Lippincott Williams & Wilkins, 2000: 1028-1043.
211. Linnoila M, Lamberg BA, Potter WZ, Gold PW, Goodwin FK. High reverse T3 levels in manic and unipolar depressed women. Psychiatry Res 1982; 6: 271-276.
212. Kjellman BF, Ljunggren JG, Beck-Friis J, Wetterberg L. Reverse T3 levels in affective disorders. Psychiatry Res 1983; 10: 1-9.
213. Kirkegaard C, Faber J. Free thyroxine and 3,3′,5′-triiodothyronine levels in cerebrospinal fluid in patients with endogenous depression. Acta Endocrinol (Copenh) 1991; 124: 166-172.
214. Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 2005; 90: 5483-5488.
215. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 89-99.
216. Fatourechi V, Klee GG, Grebe SK, Bahn RS, Brennan MD, Hay ID, McIver B, Morris JC III. Effects of reducing the upper limit of normal TSH values. JAMA 2003; 290: 3195-3196.
217. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: A clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002; 87: 1068-1072.
218. Meikle AW, Stringham JD, Woodward MG, Nelson JC. Hereditary and environmental influences on the variation of thyroid hormones in normal male twins. J Clin Endocrinol Metab 1988; 66: 588-592.
219. Hansen PS, Brix TH, Sørensen TI, Kyvik KO, Hegedüs L. Major genetic influence on the regulation of the pituitary-thyroid axis: A study of healthy Danish twins. J Clin Endocrinol Metab 2004; 89: 1181-1187.
220. Dayan CM, Saravanan P, Bayly G. Whose normal thyroid function is better - yours or mine? Lancet 2002; 360: 353.
221. Jensen EA, Petersen PH, Blaabjerg O, Hansen PS, Brix TH, Hegedüs L. Establishment of reference distributions and decision values for thyroid antibodies against thyroid peroxidase (TPOAb), thyroglobulin (TgAb) and the thyrotropin receptor (TRAb). Clin Chem Lab Med 2006; 44: 991-998.
222. Thienpont LM, Beastall G, Christofides ND, Faix JD, Ieiri T, Miller WG, Miller R, Nelson JC, Ross HA, Ronin C, Rottmann M, Thijssen JH, Toussaint B; International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) IFCC Scientific Division Working Group for Standardization of Thyroid Function Tests (WG-STFT). Measurement of free thyroxine in laboratory medicine -proposal of measurand definition. Clin Chem Lab Med 2007; 45: 563-564.